SORAFENIB (NSCLC)

Randomized Phase II study of Sorafenib plus Gemcitabine or Sorafenib plus Erlotinib
in advanced non small cell lung cancer (NSCLC) elderly or ps 2 patients

eCRFAccess
Username:
Password:

© Clinical Information Technolgy Department @ OPIS Data - 2007